BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
Monday, January 6, 2020 BiopharmaWatch Research 1 min read
Key Takeaway: BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis
Full Press Release Details
BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma.